Laveta M Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg per 5 ml, formulated to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes involved in the inflammatory cascade, contributing to the alleviation of bronchoconstriction and inflammation seen in asthma and allergic rhinitis. The synergistic action of these two agents makes Laveta M Syrup suitable for managing allergic rhinitis, chronic urticaria, and mild to moderate asthma in pediatric and adult patients. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, or gastrointestinal discomfort. Dosage should be individualized based on patient age, weight, and clinical condition, and it is recommended to use under medical supervision. Laveta M Syrup offers a convenient oral formulation, facilitating adherence in pediatric patients requiring combined antihistaminic and anti-leukotriene therapy for comprehensive allergy management.